Dr Daniel Tan
is a Consultant at the Division of Medical Oncology and a Clinician-Scientist Fellow at Genome Institute of Singapore. His main area of interest is in thoracic, head and neck malignancies and he currently leads the phase I unit where he is the principal investigator for multiple biomarker-driven early phase clinical trials including first-in-human studies. His research has won multiple international awards, including European Society of Medical Oncology Congress Travel Award, American Society of Clinical Oncology (ASCO) Merit Awards and an ASCO Young Investigator Award.
He currently serves on the Education Committee of the International Association for Study of Lung Cancer as an Associate Editor for Journal of Thoracic Oncology. His current research interests include rational application of “omics” technologies to unravel drug resistance in cancer therapeutics and accelerating the development of novel agents and biomarkers in the clinic.